Noticias Y Eventos
Misceláneas
Haga clic aquí para ver el Certificado ISO 9001:2008
Epicore announces that its USA based business has achieved ISO 9001:2008 registration. ISO 9001:2008 is a quality system based on standards published by the International Organization for Standardization. Epicore's quality system was developed with the help of consultants, Change Management Consulting Inc., and was certified by Perry Johnson Registrars Inc., who is accredited by the American National Standards Institute and American Society for Quality Board (ANAB). The Epicore ISO 9001:2008 registration covers product development, manufacture and sales functions.
Since its inception, Epicore has maintained high quality standards. The recently achieved ISO 9001:2008 registration will help ensure all our company management systems deliver consistent quality and value to our customers and other stakeholders. In the interest of improved food safety, aquaculture producers increasingly are adopting ISO 9001:2008 and other quality systems. Quality registration is increasingly becoming a requirement to secure government approvals to import and sell aquaculture feeds and feed additives.
Epicore BioNetworks Inc. is a leading producer of environmental biotechnology and animal nutrition products. It manufactures in the USA and markets worldwide to a variety of industries to reduce environmental pollution and increase operational productivity.
Epicore BioNetworks Inc. is a public corporation with a registered office in Calgary, Alberta, Canada and with shares listed on the TSX Venture Exchange (symbol EBN). [Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.]
This press release contains forward-looking statements that involve significant risks and uncertainties. The actual results, performance or achievements of the company might differ materially from the results, performance or achievements of the company expressed or implied by such forward-looking statements. Such forward-looking statements include those relating to the ability of the company to ensure delivery of consistent quality and value to stakeholders. We can provide no assurance that this will occur. We are subject to various risks, including the costs of compliance, the risk that ISO 9001 will not guarantee a successful quality system and other risks inherent in the biotechnology industry.
For more information, please contact: Mr. William P. Long (Chief Executive Officer) USA. Tel: 609-267-9118, Email: Investors@EpicoreBioNetworks.com
A sales revenue increase of 9% over prior year quarter one (Q1) to $1.11 million set a Company quarter one record. The demand for shrimp remained high throughout the quarter, as it has done for much of calendar 2011. Supply shortages caused by disease and natural disasters have pushed shrimp prices higher. Higher shrimp prices increased the demand for Epicore’s productivity enhancing products. The Epicore sales team and our distributors continued to add new customers and to pursue new applications for Epicore products. Epicore continued a major initiative to increase its science resources, which should position the Company for significant future growth and increase the reliability of its manufacturing operations. Some Q1 highlights were:
- Increased sales 9% versus prior year Q1 to $1.1 million.
- Increased gross profit 1% versus prior year Q1 to $0.6 million.
- Generated another year of positive net income ($0.06 million vs. $0.09 million in prior year Q1).
- Achieved basic and diluted earnings per share of $0.003, down from $0.004 in prior year Q1.
- Increased shareholders’ equity 2% in the quarter to $4.2 million.
- Increased cash to $1.8 million (an 8% increase in the quarter and a 51% over prior year Q1).
- Completed IFRS implementation and took advantage of the extended filing deadline for Q1.
Gross profit grew 1% due to the sales increase. Because of sales mix Epicore gross margin (gross profit as a percentage of sales) decreased. Operational expenses increased by 18% due to inflation, higher marketing travel expense, higher financial expense and one-time expense related to strategic initiatives. Quarter one fiscal 2012 results include a US federal income tax expense of $0.04 million, along with $0.02 million for New Jersey and Ecuadorian taxes. Net income of $0.06 million was lower than fiscal 2011 because of lower gross margin and higher operating expenses, as the following results show (rounded to thousands in US dollars):
2011 2010
Sales 1,114,000 1,024,000
Gross Profit 628,000 621,000
Operating Expenses 509,000 429.000
Earnings Before Tax 126,000 195,000
Income Tax Expense 62,000 104,000
Net Income 64,000 91,000
EBITDA 139,000 204,000
Cash at the end of September was $1.8 million, an increase of 8% over prior year quarter four. With these funds, expected sales revenue growth and continued relatively low operating costs, management expects there will be sufficient cash to meet the fiscal year’s financial requirements, to fund expansion of aquaculture and environmental remediation marketing efforts and to pursue new strategies for enhancing shareholder value. In support of its growth strategy, the Company anticipates additional expenditure during fiscal 2012 in property, plant and equipment, through the addition of leased capital equipment and enhancements to its production facility in New Jersey, and in product development through its ongoing R&D programs. This is expected to be financed by a combination of the Company’s cash reserves, continued positive earnings and third-party financing.
The financial statements of the company have been prepared in accordance with International Financial Reporting Standards. Epicore BioNetworks Inc. is a public corporation with a registered office in Calgary, Alberta, Canada and with shares listed on the TSX Venture Exchange (symbol EBN). [Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.]
This press release contains forward-looking statements that involve significant risks and uncertainties. The actual results, performance or achievements of the company might differ materially from the results, performance or achievements of the company expressed or implied by such forward-looking statements. Such forward-looking statements include, without limitation, those regarding the future growth of the Company, expected improvements in the quality and reliability of manufacturing operations, acceleration of the Company’s penetration into new business areas, the development plans of the company, the expected timing and results of such development and the expectation by management that there will be sufficient cash to meet the fiscal year’s financial requirements. We can provide no assurance that such development will proceed as currently anticipated, that the expected timing or results of such development will be realized or that the company will be able to generate sufficient cash to meet its obligations. We are subject to various risks, including the uncertainties of product development, markets for our products and regulatory review, our need for additional capital to fund our operations, our reliance on collaborative partners, our history of losses, and other risks inherent in the biotechnology industry.
For more information, please contact: Mr. William P. Long (Chief Executive Officer) USA. Tel: 609-267-9118, Email: Investors@EpicoreBioNetworks.com
Epicore fiscal 2011 sales revenue broke the $5 million level for the first time with a 30% increase above prior year. With increased sales and cost control, EBITDA increased 54%.
As the world slowly recovers from a severe economic downturn Epicore has grown strongly and has delivered four quarterly sales records. Demand for shrimp has been high throughout fiscal 2011. Shrimp prices have been high due to supply shortages caused by disease and natural disasters. Producers have relied on Epicore products to deliver higher productivity from their hatcheries and farms. The Epicore sales team and our distributors continued to add new customers and to pursue new applications for Epicore products. While many companies cut back in 2011, Epicore continued a major initiative to improve its science resources, which will position the Company for significant future growth and increase the reliability of its manufacturing operations. Some highlights versus prior fiscal year were:
Increased revenue from $3.8 million to $5.0 million (a 30% increase). Increased gross profit from $2.4 million to $3.0 million (a 23% increase).
Generated another year of positive net income ($0.4 million)
Increased EBITDA from $0.6 million to $0.9 million (a 54% increase).
Achieved basic and diluted earnings per share of $0.02.
Increased shareholders' equity from $3.7 million to $4.1 million (a 12% increase).
Increased cash from $1.0 million to $1.7 million (a 68% increase).
Gross profit grew 23% due to the sales increase. Because of sales mix, Epicore's gross margin did decline. Operational expenses increased by 13% in fiscal 2011 (half the fiscal 2010 increase) due to increased selling effort, inflation and IFRS conversion. Research and development expenses decreased 17% with the expiry of a research consultant contract. With the scientific program in place and the production resources being added, management expects to improve the quality and reliability of its manufacturing operations and to accelerate the Company's penetration into new business areas.
Epicore generated positive net income of $0.4 million to give Epicore its seventh consecutive year of profitable operation. Versus prior year net income decreased by $1.3 million because of the onetime recognition of the future income tax benefit of accumulated USA NOLs that was booked in 2010. One measure that ignores this onetime tax effect is EBITDA, which increased 54% over prior year from $0.6 million to $0.9 million, as the following results (in US$) show:
| (US$) | 2011 | 2010 | |
| Revenue | 5,014,600 | 3,844,100 | |
| Gross Profit | 2,956,300 | 2,396,100 | |
| Gross Margin | 59.0 % | 62.3 % | |
| Operating Expenses | 2,072,600 | 1,838,800 | |
| Net Income | 404,300 | 1,335,600 | |
| Basic/diluted net income per weighted avg. common share |
0.02 | 0.06 | |
| Shareholder's Equity | 4,109,900 | 3,658,300 | |
| Cash Balance | 1,692,600 | 1,005,300 | |
| Increase in cash | 687,300 | 193,400 |
Epicore continues to generate positive cash flows with an inflow of $0.7 million in fiscal 2011, which was $0.5 million more than fiscal 2010. Cash at the end of the year was $1.7 million. With these funds, expected sales revenue growth and continued relatively low operating costs, management expects there will be sufficient cash to meet the fiscal year's financial requirements, to fund expansion of aquaculture and environmental remediation marketing efforts and to pursue new strategies for enhancing shareholder value. In support of its growth strategy, the Company anticipates additional expenditure during fiscal 2011 in property, plant and equipment, through the addition of capital equipment and enhancements to its production facility in New Jersey, United States of America, and in product development through its ongoing R&D programs. This is expected to be financed by a combination of the Company's cash reserves, continued positive earnings and third-party financing.
The financial statements of the company have been prepared in accordance with Canadian GAAP. Epicore BioNetworks Inc. is a public corporation with a registered office in Calgary, Alberta, Canada and with shares listed on the TSX Venture Exchange (symbol EBN). [Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.]
This press release contains forward-looking statements that involve significant risks and uncertainties. The actual results, performance or achievements of the company might differ materially from the results, performance or achievements of the company expressed or implied by such forward-looking statements. Such forward-looking statements include, without limitation, those regarding the future growth of the Company, expected improvements in the quality and reliability of manufacturing operations, acceleration of the Company's penetration into new business areas, the development plans of the company, the expected timing and results of such development and the expectation by management that there will be sufficient cash to meet the fiscal year's financial requirements. We can provide no assurance that such development will proceed as currently anticipated, that the expected timing or results of such development will be realized or that the company will be able to generate sufficient cash to meet its obligations. We are subject to various risks, including the uncertainties of product development, markets for our products and regulatory review, our need for additional capital to fund our operations, our reliance on collaborative partners, our history of losses, and other risks inherent in the biotechnology industry.
For more information, please contact: Mr. William P. Long (Chief Executive Officer) USA. Tel: 609-267-9118, Email: Investors@EpicoreBioNetworks.com
Epicore anuncia el nombramiento de Megasupply de Miami, Florida, como su distribuidor de ventas locales en cuatro países de Centroamérica. Durante muchos años, Epicore ha sido un proveedor de productos de la acuicultura en América Central, principalmente a través de ventas directas: una opción viable para los grandes compradores. Con la designación como distribuidor Megasupply ha sido capaz de abrir una oficina en Choluteca, Honduras. Con un stock local de productos Epicore el servicio a los pequeños compradores de la región mejorará de manera significativa.
El CEO de Epicore, William Long, el Director de Desarrollo de Negocios en Acuicultura de Epicore, Fernando García, y el Especialista Técnico de Ventas, Jorge Ullauri, asistieron al presidente de Megasupply, José Ignacio Curiel, y a la asistente administrativa local, Sandra Velásquez, a abrir la nueva oficina (ver foto abajo). Complementando la línea de productos Epicore, Megasupply también ofrece quistes de artemia, alimentos congelados para maduración, equipos de medición y aireación para acuicultura y otros productos de calidad.
Los clientes interesados pueden visitar la oficina en el local# 12, del Hotel Gualiqueme en Choluteca, Honduras o llamar al 504-2782-6230 o al correo electrónico ventasCA@mega-supply.com. Megasupply puede ser contactado en +1 786-221-5660 o por correo electrónico a sales@mega-supply.com. Obtenga más información en www.megasupply.net.
Epicore Bionetworks Inc. es un productor líder de la biotecnología ambiental y productos de nutrición animal. Sus productos los fabrica en los EE.UU. y atiende los mercados de todo el mundo en una variedad de industrias para reducir la contaminación del medio ambiente y aumentar la productividad de las operaciones.
Epicore BioNetworks Inc. is a public corporation with a registered office in Calgary, Alberta, Canada and with shares listed on the TSX Venture Exchange (symbol EBN). [Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.]
This press release contains forward-looking statements that involve significant risks and uncertainties. The actual results, performance or achievements of the company might differ materially from the results, performance or achievements of the company expressed or implied by such forward-looking statements. Such forward-looking statements include, the development plans of the company, and the expected timing and results of such development and the expectation that a local stock of Epicore products will significantly improve service to smaller buyers in Central America. We can provide no assurance that such development will proceed as currently anticipated, that the expected timing or results of such development will be realized or that the company will be able to generate sufficient cash to meet its obligations. We are subject to various risks, including the uncertainties of product development, markets for our products and regulatory review, our need for additional capital to fund our operations, our reliance on collaborative partners, our history of losses, and other risks inherent in the biotechnology industry.
For more information, please contact: Mr. William P. Long (Chief Executive Officer) USA. Tel: 609-267-9118, Email: Investors@EpicoreBioNetworks.com
El Director de Desarrollo de la sección de Acuacultura de Epicore, Fernando García, fué uno de los ocho discursantes en la sesión de apertura de la reunión de Acuacultura en Indonesia, realizada del 4 al 6 de Octubre en Jakarta. Fernando presentó una vista general de cómo la industria Brasileña lidió con la enfermedad de IMNV por medio de cambios efectuados en las prácticas de cultivo y el uso de probióticos como el EPICIN-G2 de EPICORE.
Haga click en la imagen para leer el artículo
completo sobre la tecnología de detección de centrífugas de Epicore.
Epicore extiende su mano directamente a los camaroneros en la Provincia Noroeste de Vietnam, organizando un seminario bien concurrido en la ciudad de Mong Cai para alrededor de 35 agricultores. Esta provincia se ha trasladado completamente a vannamei y están sembrando en altas densidades entre 100 y 200/m2, usando los productos y la tecnología de Epicore para protegerse contra las condiciones ambientales.
Haga click en la imagen para leer el artículo
completo sobre la tecnología de detección de centrífugas de Epicore.
Haga click en la imagen para leer el artículo
completo sobre la tecnología de detección de centrífugas de Epicore.
Epicore se complace en anunciar el éxito de las pruebas comerciales con la nueva fórmula de su probiótico principal de acuacultura: EPICIN ®. Con más de 15 años de uso comercial en más de veinticinco países EPICIN es uno de los probióticos más ampliamente conocido en acuacultura. Su récord de entregar una calidad consistente y un excelente rendimiento en laboratorios y piscinas de acuacultura es inigualable. El objetivo de Epicore es proporcionar los mejores y más rentables, productos para la acuacultura. En este espíritu de mejora continua del producto, la investigación comenzó hace tres años para desarrollar una formulación de uso simple de EPICIN. Este trabajo desarrollo EPICIN-PILLS, una pastilla de diez gramos de 30 mm de diámetro y 11 mm de espesor. La forma pastilla se puede añadir a los sistemas de acuacultura sin hidratación previa. Su forma pre-medida hace los sistemas de dosificación lo más cerca posible a toda prueba.
Aunque originalmente concebido para las piscinas de engorde de acuacultura, EPICIN-PILLS encontró su primer uso en el Ecuador en los laboratorios camaroneros en 2008. Facilidad de uso y dosificaciones consistentes fueron grandes recursos. Debido a su alta concentración de microorganismos probióticos, el número de pastillas añadidas al sistema es bajo. Los gerentes de laboratorios informan el mismo control eficaz de los contaminantes del agua, como el amoníaco, y el mismo control de organismos patógenos como con EPICIN.
EPICIN-PILLS también está también proporcionando buenos resultados en Raceways en camaroneras ecuatorianas. El Ing. Ac. Angel Norton, biólogo a cargo de las operaciones de Raceways en la camaronera Barcelona propiedad del Grupo del Sr. Ju y ubicado en el Golfo de Guayaquil comenta: "Yo uso el tratamiento de la acuacultura EPICIN-PILLS con resultados fantásticos. Uso dos comprimidos por día por 80 toneladas de tanque durante 21 días antes y después de la siembra con 45 PL por litro. Los resultados con EPICIN-PILLS fueron asombrosos. El agua estaba limpia y sin olor. El nivel de colonias verdes dentro en el agua era menor a 200 ufc / ml versus los niveles de control hasta 600 ufc / ml. La supervivencia en los tanques de tratamiento fue de 89% versus 65% para los controles. Este producto es muy fácil de usar: simplemente tirarlo en el tanque y resuelve los problemas de contaminación.
El uso en Ecuador ha ampliado hasta transporte de larvas de camarón. El Ing. Ac. Johnnie Loayza, Biólogo de camarón de la camaronera Isla Escalante, propiedad de la Compañía Isla Bonita, situado en el Golfo de Guayaquil, comparte su experiencia con el uso de EPICIN-PILLS: "Yo uso una tableta por cada cinco toneladas de agua que se utiliza para el transporte de larvas desde un Laboratorio de la Península de Santa Elena hasta nuestra camaronera, que esta a 400 km. de distancia (un viaje de ocho horas). Con el uso de EPICIN-PILLS vemos una marcada mejoría en la salud y la actividad de post larvas, reduce el estrés y aumenta la supervivencia. Estos resultados son simplemente muy rentable para mi empresa."
Un nuevo programa recientemente lanzado en Ecuador utiliza EPICIN-PILLS en un programa de piscinas de engorde diseñado para entregar un gran número de células probióticas a un costo muy económico. El protocolo tiene ventajas sobre probióticos locales de bajo costo gracias a la alta concentración de Epicin Pills como inoculo inicial y su consistente calidad. Además, EPICIN-PILLS no tiene contaminantes gram-negativos como algunos productos más baratos si lo tienen. Epicore Ecuador SA ha lanzado el nuevo producto y el protocolo con la línea de publicidad "Sr. Acuacultor, ponga fin a su dolor de cabeza con la solución más práctico y seguro del mercado: EPICIN-PILLS."
En México, de donde nació originalmente la idea de las pastillas, las granjas de engorde utilizaron EPICIN-PILLS por primera vez en 2009. Los productores se mostraron complacidos con la facilidad de uso y reportaron buenos resultados en sus piscinas.
El tratamiento de la acuacultura para piscinas de engorde con productos especialmente formulados basados en bacterias naturales cuidadosamente selectas, proporciona una forma natural de eliminar la contaminación y para crear un entorno microbiano benéfico que inhibe el desarrollo de organismos dañinos. Las bacterias tienen una poderosa capacidad de utilizar sustancias contaminantes como el amoníaco, nitratos y nitritos en su metabolismo normal. Además, un cultivo floreciente de la bacteria natural correcta proporciona un medio ambiente "probiótico", que suprime el crecimiento de organismos dañinos. A través de estos dos mecanismos, se cría una criatura acuática más saludable que tiene una mayor vitalidad e inmunidad a las enfermedades.
Epicore conduce seminarios educativos con regularidad.
Comuníquese con Fernando García
para hora y lugar precisos.
Fernando.Garcia@EpicoreBioNetworks.com
(Ver más abajo la lista de eventos programados.)
No planeadas en este momento.